One-year mortality in patients with acute ST-elevation myocardial infarction in the Vienna STEMI registry

Bernhard Jäger1, Serdar Farhan, Karim Kalla

  • 13rd Medical Department, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Montleartstrasse 37, 1160, Vienna, Austria, bernhard.jaeger@meduniwien.ac.at.

Insights

Timely reperfusion therapy for ST-elevation myocardial infarction (STEMI) significantly reduces 1-year mortality. The Vienna STEMI network demonstrates effective care, utilizing primary percutaneous intervention (PPCI) and thrombolytic therapy (TT) to improve patient outcomes.

Area of Science:

  • Cardiology
  • Public Health
  • Emergency Medicine

Background:

  • Acute ST-elevation myocardial infarction (STEMI) treatment systems are evolving globally.
  • Registry data analysis is crucial for proving the effectiveness of STEMI networks.
  • The Vienna STEMI network employs a specific rotational system for reperfusion strategies.

Purpose of the Study:

  • To investigate the 1-year mortality rates in STEMI patients within the Vienna STEMI network.
  • To analyze the effectiveness of different reperfusion strategies (PPCI and TT) based on symptom onset time.
  • To evaluate the outcomes of a regional STEMI care system.

Main Methods:

  • Analysis of 1-year all-cause mortality data for consecutive STEMI patients over 14 months.
  • Comparison of outcomes between patients treated within 2 hours and after 2 hours of symptom onset.
  • Assessment of reperfusion strategies including primary percutaneous intervention (PPCI) and thrombolytic therapy (TT).

Main Results:

  • Patients treated within 2 hours of symptom onset had significantly lower 1-year mortality (7.4%) compared to those treated after 2 hours (13.4%).
  • No significant difference in 1-year mortality was observed between PPCI and TT when initiated within 2 hours.
  • PPCI showed a trend towards better outcomes than TT for STEMI of >2 hours duration, though not statistically significant.

Conclusions:

  • The Vienna STEMI network provides timely diagnosis, transfer, and reperfusion, leading to reassuring long-term results.
  • Pharmacological reperfusion (TT) remains a valuable backup strategy in specific cases to minimize myocardial damage.
  • This regional system highlights the importance of tailored reperfusion approaches in STEMI management.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.7K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
456
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
473
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
326
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
767